Magnetic Resonance Imaging of the Blood Vessels of the Heart

Cardiovascular Magnetic Resonance Imaging

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00001638

Enrollment

2916

Registered

1999-11-04

Start date

1997-09-29

Completion date

2009-08-03

Last updated

2022-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Disease

Keywords

Echocardiography, Heart, Gadolinium, Dobutamine, Toxicity, Adverse Events, Myocardial Infarction, Myocardial Viability, Myocardial Perfusion, Myocardial Function, Cardiovascular Disease

Brief summary

This study is directed at evaluating patients with myocardial ischemia or poor blood supply to the heart muscle due to coronary artery disease. The major objective of this study is to determine the level of safety and effectiveness of magnetic resonance imaging at diagnosing coronary artery disease. In addition, this study will allow researchers at the National Institutes of Health to see a broad spectrum of disease, preserve clinical skills, and stimulate future ideas for clinical research....

Detailed description

This is a teaching protocol. It is in a format for training physicians in the laboratory in cardiovascular MRI techniques necessary for our research protocols. It helps provide experience necessary to develop and maintain our clinical expertise with cardiovascular MRI methods. It also provides physicians in the region access to this technology.

Interventions

None listed

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* INCLUSION CRITERIA: Inclusion Criteria for All Arms of the Protocol 1. Known or suspected cardiovascular disease. 2. 18 years of age and older. 3. Able to provide informed consent.

Exclusion criteria

for All Arms of the Protocol: Patients with a contraindication to MRI scanning will be excluded. These contraindications include patients with the following devices: 1. Central nervous system aneurysm clips 2. Implanted neural stimulator 3. Implanted cardiac pacemaker or defibrillator 4. Cochlear implant 5. Ocular foreign body (e.g. metal shavings) 6. Implanted insulin pump 7. Metal shrapnel or bullet. In addition the following patient groups will be excluded: 1. Pregnant women (Patients who are uncertain as to whether they are pregnant will be required to have a screening urine or blood pregnancy test) 2. Patients with symptoms of myocardial ischemia occurring despite maximally tolerated doses of oral antianginal therapy and intravenous nitroglycerin Furthermore, the following patient groups will be excluded from studies involving the administration of MRI contrast agents: 1. lactating women unless they are willing to discard breast milk for 24 hours 2. renal disease (estimated glomerular filtration rate \[eGFR\] less than 30 ml/min/1.73 m(2) body surface area) The eGFR will be used to estimate renal function if reported by the laboratory. Otherwise, estimated glomerular filtration rate (eGFR) can be based on the Modification of Diet in Renal Disease (MDRD) study equation (see below) in subjects with stable renal function. This formula is not applicable to patients with acute renal insufficiency: eGFR (ml/min/l.73 m(2))= 175 x (serum creatinine)-l.l54 x (age)-0.203 x 0.742 (if the subject is female) x 1.212 (if the subject is black) Additional

Countries

United States

Outcome results